ANAPTYSBIO, INC (ANAB) Q3 2025 10-Q Quarterly Report

Filed: Nov 4, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

ANAPTYSBIO, INC (ANAB) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

ANAPTYSBIO, INC Q3 2025 10-Q Analysis

Risk Factors

• New regulatory risk from June 2024 U.S. Supreme Court decision reversing Chevron doctrine, increasing uncertainty in FDA regulatory reviews
• Most materially updated risk: ongoing Phase 2 trials of rosnilimab may show differing efficacy or safety, impacting development timelines and success

+3 more insights

Get deeper insights on ANAPTYSBIO, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.